SCHEMBL4776587

SCHEMBL4776587

Cc1ccc(Cl)cc1N1CCN(C(c2ccco2)C(N)C=O)CC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 5/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TSHR P16473 5/20 0.44
NPSR1 Q6W5P4 4/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
USP2 O75604 3/20 0.43
ALOX15 P16050 1/20 0.43
LMNA P02545 4/20 0.42
GAA P10253 1/20 0.42
MAPK1 P28482 1/20 0.42
MCOLN3 Q8TDD5 1/20 0.41
MAPT P10636 4/20 0.39
TP53 P04637 1/20 0.39
HSD17B10 Q99714 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4776952 0.83 LMNA (0.46) ALDH1A1TSHRNPSR1MEN1KMT2A
SCHEMBL4771297 0.81 NPSR1 (0.46) KDM4EALDH1A1TSHRNPSR1MEN1
SCHEMBL4779189 0.80 NPSR1 (0.43) ALDH1A1SMN1; SMN2TSHRNPSR1MEN1
SCHEMBL4776309 0.77 NPSR1 (0.42) ALDH1A1TSHRNPSR1MEN1KMT2A
SCHEMBL4773595 0.76 ALDH1A1 (0.43) KDM4EALDH1A1SMN1; SMN2TSHRNPSR1
SCHEMBL4770304 0.74 NPSR1 (0.39) KDM4EALDH1A1TSHRNPSR1MEN1
SCHEMBL4775611 0.72 NPSR1 (0.45) ALDH1A1TSHRNPSR1MEN1KMT2A
SCHEMBL4778604 0.70 NPSR1 (0.46) KDM4EALDH1A1TSHRNPSR1MEN1
SCHEMBL11955709 0.69 NPSR1 (0.59) ALDH1A1SMN1; SMN2TSHRNPSR1MEN1
SCHEMBL4609707 0.69 MAPT (0.47) KDM4EALDH1A1TSHRNPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed